Search results for "Lymph"

showing 10 items of 4590 documents

Melanoma of unknown primary: New perspectives for an old story

2021

Melanoma of unknown primary site (MUP) comprises 3-4 % of all melanomas. It mostly presents in lymph nodes (LNs), followed by subcutaneous sites, and visceral organs; nevertheless, there is a trend of increase in the relative incidence of visceral counterpart in recent years. Spontaneous regression of the primary lesion is a well-established theory, based on the evidence that melanoma can undergo regression at the primary site. MUP and stage-matched melanoma of known primary site (MKP) share similar prognostic factors. The survival rate of patients with MUP has been compared to those with stage-matched MKP. Multiple studies conducted before the era of novel therapy with immune checkpoint or…

0301 basic medicineOncologymedicine.medical_specialtymedicine.medical_treatment2720 Hematology610 Medicine & healthTargeted therapy03 medical and health sciences0302 clinical medicineInternal medicineEpidemiologymedicineHumansMelanomaSurvival rateHematologybusiness.industryIncidenceMelanomaIncidence (epidemiology)General MedicineHematologyImmunotherapymedicine.disease10174 Clinic for GynecologyImmune checkpointSurvival Rate030104 developmental biologyOncology030220 oncology & carcinogenesisNeoplasms Unknown Primary2730 OncologyLymph NodesGeriatrics and GerontologybusinessCritical Reviews in Oncology/Hematology
researchProduct

Pharmacogenomics and the treatment of acute myeloid leukemia.

2016

Acute myeloid leukemia (AML) is a clinically and biologically heterogeneous malignancy that is primarily treated with combinations of cytarabine and anthracyclines. Although this scheme remains effective in most of the patients, variability of outcomes in patients has been partly related with their genetic variability. Several pharmacogenetic studies have analyzed the impact of polymorphisms in genes encoding transporters, metabolizers or molecular targets of chemotherapy agents. A systematic review on all eligible studies was carried out in order to estimate the effect of polymorphisms of anthracyclines and cytarabine pathways on efficacy and toxicity of AML treatment. Other emerging gene…

0301 basic medicineOncologymedicine.medical_specialtymedicine.medical_treatmentAntineoplastic AgentsBiologyMalignancy03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGeneticsmedicineSNPHumansGenetic variabilityPharmacologyChemotherapyPolymorphism GeneticMyeloid leukemiamedicine.diseaseLeukemia Myeloid Acute030104 developmental biologyPharmacogenetics030220 oncology & carcinogenesisPharmacogenomicsImmunologyCytarabineMolecular MedicinePharmacogeneticsmedicine.drugPharmacogenomics
researchProduct

A catch-22: Interleukin-22 and cancer.

2017

Barrier surfaces of multicellular organisms are in constant contact with the environment and infractions to the integrity of epithelial surfaces is likely a frequent event. Interestingly, components of the immune system, that can be activated by environmental compounds such as the microbiota or nutrients, are interspersed among epithelial cells or directly underlie the epithelium. It is now appreciated that immune cells continuously receive and integrate signals from the environment. Curiously, such continuous reception of stimulation does not normally trigger an inflammatory response but mediators produced by immune cells in response to such signals seem to rather promote barrier integrity…

0301 basic medicineOncologymedicine.medical_specialtymedicine.medical_treatmentImmunologyBiologyPolymorphism Single NucleotideEpitheliumMalignant transformationTight JunctionsInterleukin 2203 medical and health sciences0302 clinical medicineImmune systemInternal medicineNeoplasmsmedicineImmunology and AllergyAnimalsHumansLymphocytesIntestinal MucosaReceptorWound HealingInterleukinsMicrobiotaInnate lymphoid cellEpithelial CellsEpitheliumImmunity InnateCell biology030104 developmental biologyCytokinemedicine.anatomical_structureCell Transformation NeoplasticWound healing030215 immunologyEuropean journal of immunology
researchProduct

Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?

2019

The unprecedented clinical activity of checkpoint blockade in several types of cancers has formally demonstrated that anti-tumor immune responses are crucial in cancer therapy. Durable responses seen in patients treated with immune checkpoint inhibitors (ICI) show that they can trigger the establishment of long-lasting immunologic memory. This beneficial outcome is however achieved for a limited number of patients. In addition, late relapses are emerging suggesting the development of acquired resistances that compromise the anticancer efficacy of ICI. How can this be prevented through combination therapies? We here review the functions of immune checkpoints, the successes of ICI in treating…

0301 basic medicineOrganoplatinum CompoundsImmune checkpoint inhibitorsmedicine.medical_treatmentProgrammed Cell Death 1 ReceptorLeucovorinReviewLymphocyte ActivationchemotherapyimmunomodulationB7-H1 AntigenMice0302 clinical medicineAntineoplastic Agents ImmunologicalcheckpointT-Lymphocyte SubsetsNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsTumor MicroenvironmentImmunology and AllergyCTLA-4 AntigenMolecular Targeted TherapyClinical Trials as TopicLymphokinesDrug Synergism3. Good healthNeoplasm ProteinsFluorouracillcsh:Immunologic diseases. AllergyImmunologyCancer therapyT cells03 medical and health sciencesImmune systemmedicineAnimalsHumanscancerIn patientChemotherapybusiness.industryCancermedicine.diseaseIpilimumabBlockade030104 developmental biologyDrug Resistance NeoplasmCancer cellCancer researchlcsh:RC581-607business030215 immunologyFrontiers in immunology
researchProduct

Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma

2018

In the biology of multiple myeloma (MM), immune dysregulation has emerged as a critical component for novel therapeutic strategies. This dysfunction is due to a reduced antigen presentation, a reduced effector cell ability and a loss of reactive T cells against myeloma, together with a bone marrow microenvironment that favors immune escape. The Programmed Death-1 (PD-1) pathway is associated with the regulation of T cell activation and with the apoptotic pathways of effector memory T cells. Specifically, the binding with PD-1 ligand (PD-L1) on the surface of tumor plasma cells down-regulates T cell-proliferation, thus contributing to the immune escape of tumor cells. In relapsed and/or refr…

0301 basic medicinePD-L1lcsh:Immunologic diseases. AllergyDurvalumabMini ReviewT-LymphocytesT cellProgrammed Cell Death 1 ReceptorImmunologyAntigen presentationT cellsPembrolizumabmedicine.disease_causeB7-H1 Antigen03 medical and health sciences0302 clinical medicineBone Marrowimmune dysregulationPD-L1PD-1Tumor MicroenvironmentmedicineAnimalsHumansImmunology and AllergyImmune dysregulation; Multiple myeloma; PD-1; PD-L1; T cells; Animals; B7-H1 Antigen; Bone Marrow; Humans; Multiple Myeloma; Programmed Cell Death 1 Receptor; T-Lymphocytes; Tumor MicroenvironmentMultiple myelomabiologybusiness.industryImmune dysregulationmedicine.diseasemultiple myeloma030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisbiology.proteinCancer researchNivolumabbusinesslcsh:RC581-607Frontiers in Immunology
researchProduct

Influence of Polyplex Formation on the Performance of Star-Shaped Polycationic Transfection Agents for Mammalian Cells

2016

Genetic modification (“transfection”) of mammalian cells using non-viral, synthetic agents such as polycations, is still a challenge. Polyplex formation between the DNA and the polycation is a decisive step in such experiments. Star-shaped polycations have been proposed as superior transfection agents, yet have never before been compared side-by-side, e.g., in view of structural effects. Herein four star-shaped polycationic structures, all based on (2-dimethylamino) ethyl methacrylate (DMAEMA) building blocks, were investigated for their potential to deliver DNA to adherent (CHO, L929, HEK-293) and non-adherent (Jurkat, primary human T lymphocytes) mammalian cells. The investigated vectors …

0301 basic medicinePDMAEMAPolymers and PlasticsBiocompatibilityStereochemistrynon-viralT lymphocytes02 engineering and technologyMethacrylateJurkat cellsMicelleArticlelcsh:QD241-44103 medical and health scienceschemistry.chemical_compoundlcsh:Organic chemistrymammalian cellsgene deliverychemistry.chemical_classificationGeneral ChemistryTransfectionPolymer021001 nanoscience & nanotechnologySilsesquioxane030104 developmental biologychemistrytransfectionBiophysics0210 nano-technologygene delivery; mammalian cells; non-viral; PDMAEMA; T lymphocytes; transfectionDNAPolymers
researchProduct

B-MIND: MOR208 plus bendamustine (BEN) versus rituximab (RTX) plus BEN in patients with relapsed or refractory (R-R) diffuse large B-cell lymphoma (D…

2017

TPS7571 Background: Patients ineligible for stem cell transplantation (SCT) or who relapse after SCT, and those who fail to respond to second-line or salvage chemotherapy, represent an unmet medical need for which new therapeutic strategies are required. MOR208 is a novel Fc-enhanced, humanized, monoclonal antibody directed against CD19. Significant single-agent activity of MOR208 in patients with R-R DLBCL (Jurczak et al., J Clin Oncol 34, 2016 [suppl; abstr 7545]) and enhancement of MOR208-mediated cytotoxicity by BEN in preclinical studies, provide a strong rationale to study MOR208 + BEN in patients with R-R DLBCL. Methods: B-MIND is a randomized (1:1), two-arm, multicenter, open-label…

0301 basic medicinePHASE II/III TRIALOncologyBendamustineCancer Researchmedicine.medical_specialtybusiness.industrymedicine.diseaseSurgeryTransplantation03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyRefractory030220 oncology & carcinogenesisInternal medicinemedicineRituximabIn patientStem cellbusinessDiffuse large B-cell lymphomamedicine.drugJournal of Clinical Oncology
researchProduct

A Stat6/Pten Axis Links Regulatory T Cells with Adipose Tissue Function

2017

Obesity and type 2 diabetes are associated with metabolic defects and adipose tissue inflammation. Foxp3(+) regulatory T cells (Tregs) control tissue homeostasis by counteracting local inflammation. However, if and how T cells interlink environmental influences with adipocyte function remains unknown. Here, we report that enhancing sympathetic tone by cold exposure, beta3-adrenergic receptor (ADRB3) stimulation or a short-term high-calorie diet enhances Treg induction in vitro and in vivo. CD4(+) T cell proteomes revealed higher expression of Foxp3 regulatory networks in response to cold or ADRB3 stimulation in vivo reflecting Treg induction. Specifically, Ragulator-interacting protein C17o…

0301 basic medicinePTENProteomePhysiologyAdipose tissueStimulationmTORC1Diet induced thermogenesisBorcs6 ; C17orf59 ; Foxp3 ; Pten ; Stat6 ; T Cells ; Tregs ; Adipose Tissue Function ; Cold Exposure ; Metabolic Function ; Metabolism ; Regulatory T cellsT-Lymphocytes Regulatorychemistry.chemical_compound0302 clinical medicineAdipose Tissue BrownAdipocyteUncoupling Protein 1Tissue homeostasisSTAT6ddc:616Mice Inbred BALB CFOXP3Forkhead Transcription Factorshemic and immune systemsRegulatory T cellsCell biologyCold TemperatureFoxp3FemaleMetabolic functionmedicine.symptomSignal TransductionBorcs6Adipose Tissue WhiteCold exposureT cellsTregschemical and pharmacologic phenomenaInflammationBiologyArticle03 medical and health sciencesReceptors Adrenergic betaAdipose tissue functionmedicineAnimalsC17orf59Molecular BiologyPTEN PhosphohydrolaseCell BiologyMetabolism030104 developmental biologychemistryImmunologySTAT6 Transcription Factor030217 neurology & neurosurgeryCell Metabolism
researchProduct

Intracellular fluoride influences TASK mediated currents in human T cells.

2019

The expression of Kv1.3 and KCa channels in human T cells is essential for maintaining cell activation, proliferation and migration during an inflammatory response. Recently, an additional residual current, sensitive to anandamide and A293, compounds specifically inhibiting currents mediated by TASK channels, was observed after complete pharmacological blockade of Kv1.3 and KCa channels. This finding was not consistently observed throughout different studies and, an in-depth review of the different recording conditions used for the electrophysiological analysis of K+ currents in T cells revealed fluoride as major anionic component of the pipette intracellular solutions in the initial studie…

0301 basic medicinePatch-Clamp TechniquesTime FactorsPotassium CompoundsT-LymphocytesImmunologyMagnesium ChlorideMembrane Potentials03 medical and health scienceschemistry.chemical_compoundFluorides0302 clinical medicinePotassium Channels Tandem Pore DomainPotassium Channel BlockersImmunology and AllergyHumansCells CulturedKv1.3 Potassium ChannelActivator (genetics)ChemistryPipetteAnandamideElectrophysiology030104 developmental biologyMembraneBiophysicsCell activationFluorideIntracellular030215 immunologyJournal of immunological methods
researchProduct

Intestinal dysbiosis and innate immune responses in axial spondyloarthritis

2016

Purpose of review Inflammatory innate and adaptive immune cell responses to commensal bacteria underlie the pathogenesis of human chronic inflammatory diseases. Intestinal dysbiosis has been described in patients with spondyloarthritis (SpA) and seems to be correlated with histologic and immunologic alterations. Purpose of this review is to discuss the relationship occurring between intestinal dysbiosis and innate immune responses in patients with axial SpA. Recent findings Intestinal dysbiosis and differential activation of intestinal immune responses in patients with SpA have been demonstrated. Furthermore, innate cells that appear to be involved in the pathogenesis of SpA may control int…

0301 basic medicinePathogenesis03 medical and health sciences0302 clinical medicineImmune systemRheumatologyImmunityIL-23dysbiosis; gut inflammation; IL-17; IL-23; IL-9; innate lymphoid cells; spondyloarthritis; RheumatologySpondylarthritisInterleukin 23MedicineHumansspondyloarthriti030203 arthritis & rheumatologyInnate immune systemBacteriabusiness.industrydysbiosiInnate lymphoid cellmedicine.diseaseIL-9Immunity InnateGastrointestinal MicrobiomeIntestinesIL-17030104 developmental biologyImmunologyinnate lymphoid cellDysbiosisInterleukin 17gut inflammationbusinessDysbiosis
researchProduct